134 related articles for article (PubMed ID: 9301449)
1. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET.
Nuutinen JM; Leskinen S; Elomaa I; Minn H; Varpula M; Solin O; Söderström KO; Joensuu H; Salminen E
Eur J Cancer; 1997 Jul; 33(8):1234-41. PubMed ID: 9301449
[TBL] [Abstract][Full Text] [Related]
2. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
3. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
4. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
5. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
6. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
7. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
8. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
9. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management.
Wilson CB; Young HE; Ott RJ; Flower MA; Cronin BF; Pratt BE; McCready VR; Horwich A
Eur J Nucl Med; 1995 Jun; 22(6):508-13. PubMed ID: 7556294
[TBL] [Abstract][Full Text] [Related]
10. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
[TBL] [Abstract][Full Text] [Related]
11. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
Hashizume A; Mizuno N; Kawai M; Kishida T
Hinyokika Kiyo; 2016 Jul; 62(7):383-7. PubMed ID: 27569358
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
[TBL] [Abstract][Full Text] [Related]
15. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
Büchler T; Simonová K; Fencl P; Abrahámová J
Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy.
Reinhardt MJ; Müller-Mattheis VG; Gerharz CD; Vosberg HR; Ackermann R; Müller-Gärtner HW
J Nucl Med; 1997 Jan; 38(1):99-101. PubMed ID: 8998160
[TBL] [Abstract][Full Text] [Related]
17. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
19. The role of
Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
